Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-intensity comprehensive treatment for metastatic nasopharyngeal carcinoma
ChiCTR2100043612Phase 3Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- May 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cetuximab, docetaxel, cisplatin and capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Overall Survival. Started May 2021; status: recruiting.
02
Drugs
cetuximabdocetaxelcisplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2100043612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043612.